» Articles » PMID: 6418829

Bioactivity of Gentamicin in Purulent Sputum from Patients with Cystic Fibrosis or Bronchiectasis: Comparison with Activity in Serum

Overview
Journal J Infect Dis
Date 1983 Dec 1
PMID 6418829
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Two mechanisms of potential biologic antagonism of gentamicin in purulent sputum from patients with cystic fibrosis or bronchiectasis were studied: reduction of activity by ions and antibiotic binding. Antagonism by ions was assessed by examination of the activity of gentamicin against Pseudomonas aeruginosa in dialysates of serum or sputum in ion-depleted broth. The ionic content of the dialysates increased and reflected differences in the ion content of serum and sputum. Gentamicin had significantly less activity against P aeruginosa in sputum or serum dialysates than in ion-depleted broth alone. When gentamicin was mixed with serum or sputum before dialysis, the level of antipseudomonas activity of the sputum dialysates was significantly lower than that of the serum dialysate; this finding was correlated with greater binding by sputum. Thus, both binding and antagonism by ions evidently reduce the level of bioactivity of gentamicin in serum and in sputum. Purulent sputum, whether from children with cystic fibrosis or adults which bronchiectasis, is more inhibitory than serum; the greater degree of binding, rather than differences in the composition or quantity of cations, explains this difference.

Citing Articles

Molecular Characterization of Mucus Binding.

Witten J, Samad T, Ribbeck K Biomacromolecules. 2019; 20(4):1505-1513.

PMID: 30779551 PMC: 6581564. DOI: 10.1021/acs.biomac.8b01467.


Sputum Active Polymyxin Lipopeptides: Activity against Cystic Fibrosis Pseudomonas aeruginosa Isolates and Their Interactions with Sputum Biomolecules.

Schneider-Futschik E, Paulin O, Hoyer D, Roberts K, Ziogas J, Baker M ACS Infect Dis. 2018; 4(5):646-655.

PMID: 29566483 PMC: 5952261. DOI: 10.1021/acsinfecdis.7b00238.


Antibiotic selection in the treatment of acute invasive infections by Pseudomonas aeruginosa: Guidelines by the Spanish Society of Chemotherapy.

Mensa J, Barberan J, Soriano A, Llinares P, Marco F, Canton R Rev Esp Quimioter. 2018; 31(1):78-100.

PMID: 29480677 PMC: 6159363.


The Rationale and Evidence for Use of Inhaled Antibiotics to Control Pseudomonas aeruginosa Infection in Non-cystic Fibrosis Bronchiectasis.

Dhand R J Aerosol Med Pulm Drug Deliv. 2017; 31(3):121-138.

PMID: 29077527 PMC: 5994662. DOI: 10.1089/jamp.2017.1415.


Sputum tobramycin concentrations in cystic fibrosis patients with repeated administration of inhaled tobramycin.

Ruddy J, Emerson J, Moss R, Genatossio A, McNamara S, Burns J J Aerosol Med Pulm Drug Deliv. 2012; 26(2):69-75.

PMID: 22620494 PMC: 3621259. DOI: 10.1089/jamp.2011.0942.